[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bullous-pemphigoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bullous-pemphigoid":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100266897","autoimmune-blistering-diseases-study-100266897",false,"NCT02753777","Autoimmune Blistering Diseases Study","Prevalence and Clinical Severity of Autoimmune Blistering Diseases","AIBD","Inclusion Criteria:\n\n* Gender\u002FAge: Males or females above 18 years old\n* Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid\n* Subjects able to give informed consent\n\nExclusion Criteria:\n\n* Patients who are under age 18 years.\n* Patients without pemphigus or pemphigoid diseases\n* Penn employees\n* Penn students\n* Cognitively impaired persons","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","3 Years","OBSERVATIONAL","Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.",[26,27,28],"Pemphigus Vulgaris","Pemphigus Foliaceus","Bullous Pemphigoid","RECRUITING","2026-03-24",{"date":32,"type":33},"2026-03-30","ACTUAL",{"date":35,"type":4},"2016-04",{"date":37,"type":21},"2030-01-02",{"name":39,"class":40},"University of Pennsylvania","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100552894","deciphering-il-17-dependant-inflammatory-response-in-bullous-pemphigoid-100552894","NCT06479018","Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid","Identification and Functional Characterization of the Cellular and Molecular Actors of the IL-17B\u002FIL-17RB Axis in Bullous Pemphigoid","BP-IL17RB","Inclusion Criteria:\n\n* patients with Bullous Pemphigoid (BP) using the following criteria: clinical features typical of BP with presence of at least three out of four well-established criteria by Vaillant et al.47; subepidermal blister on skin biopsy; and deposits of IgG and\u002For C3 in a linear pattern along the epidermal basement membrane zone by direct IF.\n* patient agreed to participate to the study\n* patient affiliated to the French Healthcare System\n\nExclusion Criteria:\n\n* patient that does not have the ability to give its written informed consent before inclusion in the study\n* patient with a pemphigoid gestationis\n* patient with a relapse of Bullous Pemphigoid\n* patient with Bullous Pemphigoid that already received local superpotent corticotherapy during the last 14 days before inclusion or systemic corticoid treatment during the last 28 days before inclusion\n* anemic patient (hemoglobin \\\u003C 10 g\u002FdL)",{"count":50,"type":21},140,"INTERVENTIONAL",[53],"NA","Bullous pemphigoid (BP) is the most frequent autoimmune skin disease and mainly affects elderly individuals. BP classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense itches. However, BP is characterized by a large spectrum of clinical presentations allowing to distinguish between typical (with blisters) and atypical forms (non bullous, mucosal damage).\n\nHigh potency topical steroids and systemic steroids are the current first line intention treatments. While very efficient, these therapies are non-targeted and cause numerous side-effects, especially in these elderly patients that are the most affected. Furthermore, around 30% of BP patients will relapse during the first year of treatment when corticotherapy is decreased or stopped.\n\nThe investigators and others have highlighted the presence of Il-17 family belonging-inflammatory cytokines in BP patients. Their functions in the amplification of the inflammatory response and in the mechanisms of relapse have to be precisely determined in order to develop innovative therapeutic approaches and to move forwards precision medicine.",[28],[57,58,59],"Bullous pemphigoid","IL-17 family","inflammatory response","2024-06-26",{"date":62,"type":33},"2024-06-27",{"date":64,"type":33},"2022-02-10",{"date":66,"type":21},"2026-01-10",{"name":68,"class":40},"CHU de Reims",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100467389","validation-of-a-simplified-severity-score-investigator-global-assessment-iga-in-bullous-pemphigoid-100467389","NCT05366127","Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid","IGA score","Inclusion Criteria:\n\n* Consecutive adult patients aged ≥ 18 years\n* Newly diagnosed or relapsing BP\n* Clinical features suggestive of classic BP AND suggestive histological features AND deposition of IgG and\u002F or C3 deposits on the dermal epiderma junction, AND detection of circulating anti-epidermal antibodies labelling the epidermal side of salt-split skin\n* Patient having read and understood the information letter and not opposed to participation\n* Must be willing and able to adhere to all specified requirements, including but not limited to adherence to the follow-up visits\n\nExclusion Criteria:\n\n* Predominant or exclusive mucosal involvement leading to suspect the diagnosis of mucous membrane pemphigoid\n* Pemphigoid gestationis\n* Linear IgA dermatosis (predominant or exclusive IgA deposits on the DEJ)\n* Skin lesions suggesting the diagnosis of epidermolysis bullosa acquisita (skin fragility, atrophy, milia)",{"count":20,"type":21},"The aim of the study is to validate a global and simple score : IGA (Investigator Global Assessment) score for the evaluation of the extent and severity of the disease in patients with bullous pemphigoid",[28],"NOT_YET_RECRUITING","2022-05-04",{"date":83,"type":33},"2022-05-09",{"date":85,"type":21},"2022-07-01",{"date":87,"type":21},"2026-07-30",{"name":89,"class":40},"University Hospital, Rouen",11]